Effects of culture conditions on N-glycolylneuraminic acid (Neu5Gc) content of a recombinant fusion protein produced in CHO cells
- PMID: 20039310
- DOI: 10.1002/bit.22644
Effects of culture conditions on N-glycolylneuraminic acid (Neu5Gc) content of a recombinant fusion protein produced in CHO cells
Abstract
CHO cells express glycoproteins containing both the N-acetylneuraminic acid (Neu5Ac) and minor amounts of the N-glycolylneuraminic acid (Neu5Gc) forms of sialic acid. As Neu5Gc is not expressed in humans and can be recognized as a foreign epitope, there is the potential for immunogenicity issues for glycoprotein therapeutics. During process development of a glycosylated fusion protein expressed by CHO cells, a number of culture conditions were identified that affected the Neu5Gc content of the recombinant glycoprotein. Sodium butyrate (SB), a well-known additive reported to enhance recombinant protein productivity in specific cases, minimally affected product titers here, but did decrease Neu5Gc levels by 50-62%. A shift in culture temperature to a lower value after the exponential growth phase was used to extend the culture period. It was found that the Neu5Gc levels were 59% lower when the temperature shift occurred later near the stationary phase of the culture compared to an early-temperature shift, near the end of the exponential growth phase. Studies on the effects of pCO(2) with this product showed that the Neu5Gc levels were 46% lower at high pCO(2) conditions (140 mmHg) compared to moderate pCO(2) levels (20-80 mmHg). Finally, a comparison of sodium carbonate versus sodium hydroxide as the base used for pH control resulted in a reproducible 33% decrease in Neu5Gc in bioreactors using sodium hydroxide. These results are of practical importance as SB is a commonly tested additive, and the other factors affecting Neu5Gc can conveniently be used to reduce or control Neu5Gc in processes for the manufacture of glycoprotein therapeutics.
(c) 2009 Wiley Periodicals, Inc.
Similar articles
-
Determination and distribution of N-acetyl- and N-glycolylneuraminic acids in culture media and cell-associated glycoconjugates from human malignant mesothelioma and adenocarcinoma cells.Biomed Chromatogr. 2006 May;20(5):434-9. doi: 10.1002/bmc.573. Biomed Chromatogr. 2006. PMID: 16177958
-
Osmolality as a lever to modulate the N-glycolylneuraminicacid (Neu5Gc) level of a recombinant glycoprotein produced in Chinese hamster ovary cells.Biotechnol Prog. 2020 Nov;36(6):e3038. doi: 10.1002/btpr.3038. Epub 2020 Jul 10. Biotechnol Prog. 2020. PMID: 32542945
-
Identification of cell culture conditions to control N-glycosylation site-occupancy of recombinant glycoproteins expressed in CHO cells.Biotechnol Bioeng. 2009 Aug 15;103(6):1164-75. doi: 10.1002/bit.22348. Biotechnol Bioeng. 2009. PMID: 19418565
-
N-glycolylneuraminic acid conjugates: implications of their absence in mammalian biochemistry.Indian J Biochem Biophys. 2003 Aug;40(4):217-25. Indian J Biochem Biophys. 2003. PMID: 22900313 Review.
-
Why Is N-Glycolylneuraminic Acid Rare in the Vertebrate Brain?Top Curr Chem. 2015;366:31-54. doi: 10.1007/128_2013_419. Top Curr Chem. 2015. PMID: 23471785 Free PMC article. Review.
Cited by
-
Integration Approaches to Model Bioreactor Hydrodynamics and Cellular Kinetics for Advancing Bioprocess Optimisation.Bioengineering (Basel). 2024 May 27;11(6):546. doi: 10.3390/bioengineering11060546. Bioengineering (Basel). 2024. PMID: 38927782 Free PMC article. Review.
-
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics.Crit Rev Biotechnol. 2015 Jun;35(2):235-54. doi: 10.3109/07388551.2013.834293. Epub 2013 Oct 24. Crit Rev Biotechnol. 2015. PMID: 24156398 Free PMC article. Review.
-
Enhancement of sialylation in rIgG in glyco-engineered Chinese hamster ovary cells.Cytotechnology. 2020 Jun;72(3):343-355. doi: 10.1007/s10616-020-00381-z. Epub 2020 Mar 3. Cytotechnology. 2020. PMID: 32125558 Free PMC article.
-
Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma.Theranostics. 2022 Jul 18;12(13):5615-5630. doi: 10.7150/thno.56736. eCollection 2022. Theranostics. 2022. PMID: 35966592 Free PMC article.
-
Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy.Biologics. 2018 Dec 21;13:1-12. doi: 10.2147/BTT.S114530. eCollection 2019. Biologics. 2018. PMID: 30613134 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials